公开(公告)号：US12124920B2

公开(公告)日：2024-10-22

申请号：US17768430

申请日：2020-10-03

申请人： Lupin Limited

发明人： Imran Shaikh ,  Mukul Dalvi ,  Xian-Ming Zeng ,  David Schaller ,  Cameron Alberg

IPC分类号： A61M15/00 ,  G06M1/04 ,  G06M1/08 ,  G06M1/24 ,  A61M16/00

CPC分类号： G06M1/248 ,  A61M15/0075 ,  A61M15/009 ,  G06M1/04 ,  G06M1/045 ,  G06M1/08 ,  G06M1/083 ,  A61M2016/0015 ,  A61M2205/3306 ,  A61M2205/3368 ,  A61M2205/3375 ,  A61M2205/583 ,  A61M2205/584

摘要： Provided herein are new devices for indicating the status of events, such as the number of relevant events that are remaining and/or that have already occurred up to the present moment and to related devices, systems, and methods. In some aspects, the event-related indicator devices of the invention are used within larger dispensing devices or systems, e.g., to provide the status of administration of a substance contained therein (e.g., a drug). In an exemplary embodiment, the indicator devices find particular utility within medicament dispensers, such as metered dose inhalers, to provide a visual indication of the status of doses having been or remaining to be administered.

公开(公告)号：US20230049917A1

公开(公告)日：2023-02-16

申请号：US17789343

申请日：2020-12-26

申请人： Lupin Limited

发明人： Rajender Kumar Kamboj ,  Dhananjay Sadashiv Bakhle ,  Chirag Anilkumar Shah

IPC分类号： A61K31/5375 ,  A61K9/20 ,  A61K31/352 ,  A61K31/195 ,  A61K31/137 ,  A61P5/20

摘要： The invention provides for a compound having the structure of Formula (I) to Formula (VI), including Compounds 1 to 6, their pharmaceutically acceptable salts, and compositions comprising thereof. This invention further includes methods of their use for the treatment of diseases or disorders associated with the modulation of calcium sensing receptors (CaSRs), including secondary hyperparathyroidism associated with chronic kidney disease in a subject in need thereof. This disclosure further relates to a process for the preparation of said pharmaceutical compositions.

公开(公告)号：US11278502B2

公开(公告)日：2022-03-22

申请号：US16146237

申请日：2018-09-28

申请人： LUPIN LIMITED

发明人： Shirishkumar Kulkarni ,  Satish Kumar Dalal ,  Harshal Jahagirdar ,  Kishore Kumar Konda

IPC分类号： A61K9/50 ,  A61K47/38 ,  A61K31/165 ,  A61K9/20 ,  A61K47/32

摘要： The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cmax to Cmin peak to trough variation over a period of at least 12 hrs.

公开(公告)号：US10696636B2

公开(公告)日：2020-06-30

申请号：US16063732

申请日：2016-12-15

申请人： Lupin Limited

发明人： Girij Pal Singh ,  Dhananjai Shrivastava ,  Harishchandra Sambhaji Jadhav ,  Pramod Sudhakar Utekar ,  Digambar Yashwant Salunke

IPC分类号： C07D213/803

摘要： The present invention provides compound of formula (XVII), wherein P is hydroxyl protecting group; R2 and R3 are independently lower alkyl or R2 and R3 can be alkyl and joined to form a 5-, 6- or 7-membered ring; R4 is lower alkyl, and process for its preparation.

公开(公告)号：US10556069B2

公开(公告)日：2020-02-11

申请号：US15121430

申请日：2015-02-23

申请人： LUPIN LIMITED

发明人： Vishwajit Bhide ,  Raghuram Amperayani Pattabhi ,  Rohini Pimple ,  Bishu Choubey

IPC分类号： A61M15/00

摘要： An inhaler device comprising: a housing (2), a base plate (4) covering the housing (2), a medicament holder (10) integrated with the base plate (4), a mouthpiece (3) sitting over the base plate (4), a lid (1) which covers the mouthpiece (3), at least one piercing element (11), an actuating member (5), a spring (12), and is characterized in that the inhaler device is a two hinges system (6,8) wherein the base plate (4) is joined to hinge (6); the mouthpiece (3) and the lid (1) are joined to the hinge (8).

公开(公告)号：US20190275012A9

公开(公告)日：2019-09-12

申请号：US16320902

申请日：2017-07-28

申请人： Lupin Limited

发明人： Gagan Kukreja ,  Nageswara Rao Irlapati ,  Arun Rangnath Jagdale ,  Gokul Keruji Deshmukh ,  Vinod Popatrao Vyavahare ,  Kiran Chandrashekhar Kulkarni ,  Neelima Sinha ,  Venkata P. Palle ,  Rajender Kumar Kamboj

IPC分类号： A61K31/429 ,  A61P35/02 ,  A61P37/00 ,  A61P11/00

摘要： Disclosed are compounds of the general formula (I), wherein R1-R3 are as defined herein, for use as MALT1 inhibitors in the treatment of autoimmune and inflammatory diseases or disorders. Methods of synthesizing the compounds are also disclosed. Also disclosed are pharmaceutical compositions containing a compound of the invention and a method of treating a patient for an autoimmune or an inflammatory disease or disorder, for example, a cancer, by administering a compound of the invention.

公开(公告)号：US20190256498A1

公开(公告)日：2019-08-22

申请号：US16316213

申请日：2017-07-07

申请人： LUPIN LIMITED

发明人： Palash SANPHUI ,  Radhakrishna Bhikaji SHIVDAVKAR ,  Gurvinder Pal SINGH ,  Purna Chandra RAY ,  Girij Pal SINGH ,  Vikas Ashokrao SADAPHAL ,  Lalitkumar Dilipising RAJPUT ,  Hemraj Mahadeorao LANDE

IPC分类号： C07D403/14

摘要： The present invention provides novel crystalline form L1 of daclatasvir dihydrochloride wherein the diffraction peaks at 5.35, 6.04, 6.76, 8.65, 9.21, 10.35, 10.32, 10.75, 11.04, 11.66, 12.95, 13.56, 16.06, 18.11, 20.58, 22.18, 23.27±0.2 degree two theta in an X-ray diffraction pattern. The present invention provides novel crystalline form L2 of daclatasvir dihydrochloride wherein the diffraction peaks at 8.27, 9.54, 11.06, 13.61, 15.34, 19.01, 22.26, 23.24, 24.73, 25.35±0.2 degree two theta in an X-ray diffraction pattern. The present invention further provides process for preparation of crystalline forms L1 and L2 of daclatasvir dihydrochloride.

公开(公告)号：US10377712B2

公开(公告)日：2019-08-13

申请号：US15577102

申请日：2016-05-26

申请人： LUPIN LIMITED

发明人： Palash Sanphui ,  Ananda Pundlik Sapdhare ,  Arunkumar Digambar Patil ,  Hemraj Mahadeorao Lande ,  Gurvinder Pal Singh ,  Puma Chandra Ray ,  Nandu Baban Bhise ,  Girij Pal Singh ,  Mithun Dasharath Surwase ,  Shantanu Gokuldas Varade ,  Govind Dnyanoba Ausekar ,  Radhakrishna Bhikaji Shivdavkar

IPC分类号： C07D209/48 ,  C07C315/04

摘要： The present invention provides an improved process for preparation of an intermediate of apremilast. The present invention also provides an improved process for preparation of apremilast. This invention also provides novel polymorphs of apremilast. The present invention also provides pharmaceutical compositions of novel polymorphs of apremilast. This invention also provides a process for preparation of novel polymorphs of apremilast, which are cost-effective, robust, and viable at plant scale.

公开(公告)号：US20190135803A1

公开(公告)日：2019-05-09

申请号：US16095424

申请日：2017-04-12

申请人： LUPIN LIMITED

发明人： Tushar Nandkumar DESPANDE ,  Dnyaneshwar Tukaram SINGARE ,  Yogesh Dadaji PAWAR ,  Yuvraj Atmaram CHAVAN ,  Purna Chandra RAY ,  Girij Pal SINGH

IPC分类号： C07D455/06

CPC分类号： C07D455/06 ,  C07B2200/05

摘要： The present invention provides process for preparation of dihydroxy benzoquinoline compound (III) comprising reacting dihydroxy isoquinoline compound (IV) or a salt thereof with (2-acetyl-4-methyl-pentyl)-trimethyl-ammonium iodide (V) and further converting it to tetrabenazine (I) and deutetrabenazine (II).

公开(公告)号：US10259790B2

公开(公告)日：2019-04-16

申请号：US15947422

申请日：2018-04-06

申请人： LUPIN LIMITED

发明人： Narendra Dattatray Mane ,  Sagar Purushottam Nehate ,  Himanshu Madhav Godbole ,  Girij Pal Singh

IPC分类号： C07D215/14

摘要： The present invention is directed to polymorphic forms of Pitavastatin sodium and processes for preparation of the same.